![logo.png](https://static.wixstatic.com/media/f25ca0_adb367f8d4d340b28cef8192105650d8~mv2.png/v1/fill/w_524,h_144,al_c,lg_1,q_85,enc_auto/logo.png)
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (CIGB)
Centre for Genetic Engineering and Biotechnology is a(( closed-loop research and technology centre. Through research and development, they have produced vaccines of international standards. Some vaccines made by CIGB include the Hepatitis B vaccine and an HPV vaccine comparable to CERVIRAX. Of great significance, is that CIGB developed a vaccine for the management of SARS-COVID-19, Abdala.
​
PRODUCT: Abdala
Abdala is a vaccine against SARS-COVID-19 that has completed its phase three trials and is currently on the list to be approved by the World Health Organization for emergency use. Abdala has a ninety-three (93%) efficacy against SARS COV-19 and has been used in children from age 5 years and upwards. This is significant as most other vaccines are still experimenting and evaluating accurate doses for children btw ages 5 and 12 years Abdala is proven to have eight-month protection after administration in three doses fourteen days apart. Abdala has a one hundred per cent (100%) efficacy in preventing severe disease and a one hundred per cent (100%) efficacy in preventing death in immunized patients. Abdala is stable at 2-8 degrees Celsius with no need to freeze, making its cold chain logistics easy to manage.
​
There have been very few side effects, with irritation at the injection site and mild drowsiness for 24 hours being the most common.
![ablaba.jpg](https://static.wixstatic.com/media/f25ca0_90ba66308417487f9d37b9d2b5b9acba~mv2.jpg/v1/fill/w_630,h_427,al_c,lg_1,q_80,enc_auto/ablaba.jpg)